COVID guidance for managing inpatient hyperglycaemia

Concise Advice on Inpatient Diabetes during COVID-19 - Guidance for managing inpatient hyperglycaemia

Practical guidance for managing inpatient hyperglycaemia during COVID-19

Concise advice on inpatient diabetes - guidance for managing inpatient hyperglycaemia

Discipline:

Diabetes

Clinical taxonomy:

COVID-19

Inpatient care

Treatments for diabetes

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Resource taxonomy:

Guidelines

Address for correspondence: ABCD (Diabetes Care) Ltd, Miria House, 1683b High Street, Knowle, Solihull, West Midlands, B93 0LL

Telephone: 01675 477602 Facsimile: 01361 331 811 Email: info@abcd.care

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361,whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd

ABCD Corporate Pharma Sponsors; Gold: AstraZeneca, Lilly, Novo Nordisk Ltd, Sanofi Diabetes; Bronze: Napp Pharmaceuticals Limited

ABCD Corporate Pump & Device Supporters, Gold: Abbott Laboratories Ltd, Roche Diabetes Care, Ypsomed Ltd; Silver: Advanced Therapeutics (UK) Ltd, Medtronic Ltd; Bronze: Dexcom, Insulet International Ltd

Read the ABCD statement on pharmaceutical industry funding

Concise Advice on Inpatient Diabetes during COVID-19 - Guidance for managing inpatient hyperglycaemia

Information for HCPs

ABCD Webinar Series

Search form

You are here

Concise Advice on Inpatient Diabetes during COVID-19 - Guidance for managing inpatient hyperglycaemia

Information for HCPs

ABCD Webinar Series